
About NGM Biopharmaceuticals
NGM Biopharmaceuticals is a publicly listed company based in San Francisco (United States) founded in 2007 by Jin-Long Chen. Biologics are developed for cardio-metabolic and liver diseases. NGM Biopharmaceuticals has raised $358.87 million across 8 funding rounds from investors including Merck, The Column Group and Greenspring Associates. The company has 71 employees. NGM Biopharmaceuticals was last valued at $975 million in April 2019. Its chief executive, as recorded, is David J Woodhouse. NGM Biopharmaceuticals offers products and services including NGM120 and Pipeline Drugs. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Gastroenterology. Its legal entity is NGM Biopharmaceuticals, Inc. Its competitors include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.
- Headquarters San Francisco, United States
- Employees 71
- Founders Jin-Long Chen
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ngmbio.com
- Social LinkedIn X
- Legal Name Ngm Biopharmaceuticals, Inc.
- Annual Revenue$330.53 M (USD)14.61as on Dec 31, 2025
- Net Profit$22.2 M (USD)70.68as on Dec 31, 2025
- EBITDA$39.07 M (USD)12.67as on Dec 31, 2025
- Total Equity Funding$358.87M (USD)
in 8 rounds
- Latest Funding Round$142.04M (USD), Post-IPO
Jul 2024
- InvestorsMerck
& 8 more
- Employee Count71
Products & Services of NGM Biopharmaceuticals
NGM Biopharmaceuticals offers a comprehensive portfolio of products and services, including NGM120 and Pipeline Drugs.
Drug candidate for treating Hyperemesis Gravidarum in clinical trials
In-house developed drugs addressing various global diseases
Funding Insights of NGM Biopharmaceuticals
NGM Biopharmaceuticals has successfully raised a total of $358.87M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $142.04 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $358.87M
- Total Rounds 8
- Last Round Post-IPO — $142.04M
- First Round $25.5M
(Feb 2008)
- Investors Count 9
All 8 funding rounds of NGM Biopharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $142.04M | Post-IPO | – | – | – |
| Mar 2015 | $106M | Series D | – | Merck | – |
| Feb 2015 | $57.5M | Series D | – | Prospect Venture Partners, TCG | |
| Jul 2013 | $50M | Series C | – | – | |
| May 2013 | $13.49M | Series C | – | – | – |
| Nov 2011 | $55.39M | Series C | – | – | – |
| Mar 2010 | $51M | Series B | – | – | |
| Feb 2008 | $25.5M | Series A | – | Prospect Venture Partners, Rho Capital Partners | – |
Last known valuation $975M (Apr 2019). 9 investors in total: 9 institutional.
Investors in NGM Biopharmaceuticals
NGM Biopharmaceuticals has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, The Column Group and Greenspring Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in US life sciences and healthtech firms. | prospectventures.com | Palo Alto, United States | ||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands. | topspincp.com | Mamaroneck, USA | ||
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
Diversified investment management firm | 2000 | greenspringassociates.com | Owings Mills, United States | |
| takedaventures.com | ||||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
| tichenorventures.com | ||||
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for NGM Biopharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NGM Biopharmaceuticals
39 people are tracked at NGM Biopharmaceuticals (13 in leadership, 10 in board & advisors, 16 in team); the tracked headcount is 71.
| Name | Role | Group |
|---|---|---|
David J Woodhouse | CEO | Leadership |
Jin-Long Chen | Founder | Leadership |
Wendy Yeh | Chief Medical Officer | Leadership |
Lulu Sterling | Senior Director, Biometrics | Leadership |
Vladimir Hanes | VP, Clinical Development Oncology | Leadership |
Diana Peng Bockus | Head of Business Development | Leadership |
Julie Roda | Director, Head Of Translational Science | Leadership |
Mahi Saraf | Associate Director, People & Culture | Leadership |
Fatima Larry | Director, Medical Writing | Leadership |
Kara Calhoun | Sr. Vice President, CMC & Process Development | Leadership |
Jean-Frederic Viret | Chief Financial Officer And Corporate Secretary (april 2024) | Leadership |
Scott Giese | Director, Downstream CMC | Leadership |
Ayako Kuroda | Associate Director, In Vivo Resources | Leadership |
Michael S. Brown | Chairman of Scientific Advisory Board | Board & advisors |
Grant Heidrich | Special Advisor | Board & advisors |
Roger M. Perlmutter | Director | Board & advisors |
Michael Fischbach | Scientific Advisory Board Member | Board & advisors |
Robert D. Schreiber | Scientific Advisory Board Member | Board & advisors |
Joseph L. Goldstein | Scientific Advisory Board Member | Board & advisors |
Arthur D. Levinson | Special Advisor | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for NGM Biopharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NGM Biopharmaceuticals
NGM Biopharmaceuticals is a publicly listed company on the GETTEX with ticker symbol 0IK in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Apr 2019
- Listed onNASDAQ: NGM
- Listed entityNGM Biopharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINGB00BS3DYQ52
- Share price8.21 EUR (-2.15% on the day) · 2026-05-11
- Market capitalisation1,560,000,000.00 EUR
- Price to earnings54.7
- Volume (last session)210
- Analyst consensusNo rating
Financials of NGM Biopharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 281.3M EUR | 18.9M EUR | 33.2M EUR |
| 2024 | 245.4M EUR | 11.1M EUR | 29.5M EUR |
| 2023 | 246.6M EUR | 29.3M EUR | 40.6M EUR |
| 2022 | 172.3M EUR | 15.7M EUR | 22.5M EUR |
| 2021 | 121.6M EUR | 12.8M EUR | 19.7M EUR |
Detailed financial statements for NGM Biopharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NGM Biopharmaceuticals
4 dated milestones of NGM Biopharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.
- Founded NGM Biopharmaceuticals is founded.
- Funding First funding round of $25.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $142.0M.
Competitors of NGM Biopharmaceuticals
NGM Biopharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of NGM Biopharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NGM Biopharmaceuticals
The website of NGM Biopharmaceuticals (ngmbio.com) receives about 3.3K visits a month and ranks #4,587,249 among all websites worldwide, #5,487 in Biotechnology and Pharmaceuticals.
- Monthly visits3.3K
▼ 11.7% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,587,249
among all websites
- Category rank#5,487
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit1.8
- Average visit25 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with NGM Biopharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novotech-cro.com | 100% | 49.2K | #897,361 | View details | |
| numerate.com | 96% | View details | |||
summitplc.com | summitplc.com | 93% | – | ||
| bioseekinc.com | 93% | View details | |||
| diabetesaustralia.com.au | 57% | #282,620 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for NGM Biopharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as NGM Biopharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ngm Biopharmaceuticals
Complete news archive for NGM Biopharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NGM Biopharmaceuticals
NGM Biopharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
NGM Biopharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
David J Woodhouse is the CEO of NGM Biopharmaceuticals, as recorded in our data.
NGM Biopharmaceuticals is a funded company, having raised a total of $358.87M across 8 funding rounds to date. The company's 1st funding round was a Series A of $25.5M, raised on Feb 2008.
NGM Biopharmaceuticals has 71 employees.
Annual revenue of NGM Biopharmaceuticals is $330.53M as on Dec 31, 2025.
NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.
NGM Biopharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics.
NGM Biopharmaceuticals offers NGM120 and Pipeline Drugs.
Yes, NGM Biopharmaceuticals is publicly traded on GETTEX under the ticker symbol 0IK.
NGM Biopharmaceuticals has 9 investors. Key investors include Merck, The Column Group, Greenspring Associates, Prospect Venture Partners, and Topspin Consumer Partners.
The valuation of NGM Biopharmaceuticals is $975M as of Apr 2019.
